ArticleEULAR rheumatology open2026
Early experience of avacopan for ANCA-associated vasculitis in an Australian paediatric population: a case series.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avacopan, a complement inhibitor targeting C5a receptor, is a novel and effective agent in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in adults. However, paediatric data of efficacy and safety are scarce. This report outlines our nationwide experience with avacopan for AAV in 8 adolescents. Avacopan was used as an adjunct following induction with glucocorticoids, rituximab, and/or cyclophosphamide at a median of 2 months postdiagnosis. There was good clinical improvement in 5 of the patients with an ability to wean steroid therapy; however, for 3, the disease progressed to end-organ damage despite avacopan introduction. There were no significant adverse events or serious infections reported with follow-up of a median of 6 months of avacopan use. The efficacy for most and short-term safety in all our cohort of avacopan is reassuring in the infancy of paediatric use and supports the need for further research in this orphan disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.